Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity - PubMed (original) (raw)
. 1995 Aug 15;55(16):3598-603.
Affiliations
- PMID: 7543017
Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity
J W Hodge et al. Cancer Res. 1995.
Abstract
At least two signals are required for the activation of naive T cells by antigen-bearing target cells: an antigen-specific signal, delivered through the T-cell receptor, and a costimulatory signal delivered through the T-cell surface molecule CD28 by its natural ligand B7-1. The immunological benefit of coexpression of B7 with target antigen has been demonstrated with the use of several retroviral systems to transfect antigen-bearing cells. Although engineering recombinant constructs with genes for two or more antigens can mediate the dual expression of those antigens, disadvantages of this approach include the time for construction of each desirable combination and the inability to control differential expression levels of each gene product. An alternative approach would utilize separate constructs that could be admixed appropriately before administration. In this report we describe the functional consequences of the admixture of recombinant vaccinia murine B7-1 (rV-B7) to recombinant vaccinia expressing the human carcinoembryonic antigen gene (rV-CEA). Coinfection of cells resulted in high levels of cell surface expression of both the CEA and B7 molecules. Immunization of mice with various ratios (1:3, 1:1, 3:1) of rV-CEA and rV-B7 demonstrated that an admixture of rV-CEA and rV-B7 at a 3:1 ratio resulted in the generation of optimal CEA-specific T-cell responses. Next, we examined the efficacy of this admixture on antitumor activity. Typically, injection of murine carcinoma cells expressing CEA leads to the death of the host. One immunization of C57BL/6 mice with rV-CEA:rV-B7 (3:1) resulted in no tumor establishment. In contrast, administration of rV-CEA or rV-B7 alone had little or no antitumor effects. These studies demonstrate the advantages of the use of recombinant vaccinia viruses to deliver B7 molecules in combination with a tumor-associated antigen. The availability of the rV-B7 single construct and the ability to alter the B7 ratio could also have potential utility when coinfecting rV-B7 with recombinant vaccinia viruses containing genes for infectious agents or other tumor-associated antigen genes.
Similar articles
- Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Hodge JW, et al. Clin Cancer Res. 2003 May;9(5):1837-49. Clin Cancer Res. 2003. PMID: 12738742 - Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
Hodge JW, Abrams S, Schlom J, Kantor JA. Hodge JW, et al. Cancer Res. 1994 Nov 1;54(21):5552-5. Cancer Res. 1994. PMID: 7522961 - The diversity of T-cell co-stimulation in the induction of antitumor immunity.
Schlom J, Hodge JW. Schlom J, et al. Immunol Rev. 1999 Aug;170:73-84. doi: 10.1111/j.1600-065x.1999.tb01330.x. Immunol Rev. 1999. PMID: 10566143 Review. - Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.
Schlom J, Kantor J, Abrams S, Tsang KY, Panicali D, Hamilton JM. Schlom J, et al. Breast Cancer Res Treat. 1996;38(1):27-39. doi: 10.1007/BF01803781. Breast Cancer Res Treat. 1996. PMID: 8825120 Review.
Cited by
- Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma.
Portal DE, Weiss RE, Wojtowicz M, Mansour A, Monken C, Mehnert JM, Aisner JA, Kane M, Nishioka J, Aisner S, Peters S, Stein MN, Kim IY, Mayer TM, Shih W, Gulley J, Streicher H, Singer EA, Lattime EC. Portal DE, et al. Cancer Gene Ther. 2020 Jun;27(6):438-447. doi: 10.1038/s41417-019-0112-z. Epub 2019 Jun 20. Cancer Gene Ther. 2020. PMID: 31222182 Free PMC article. Clinical Trial. - Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Guo ZS, et al. J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. J Immunother Cancer. 2019. PMID: 30626434 Free PMC article. Review. - Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.
Aitken AS, Roy DG, Bourgeois-Daigneault MC. Aitken AS, et al. Biomedicines. 2017 Jan 4;5(1):3. doi: 10.3390/biomedicines5010003. Biomedicines. 2017. PMID: 28536346 Free PMC article. Review. - Therapeutic cancer vaccines.
Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL. Schlom J, et al. Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Adv Cancer Res. 2014. PMID: 24889529 Free PMC article. Review. - T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
Barach YS, Lee JS, Zang X. Barach YS, et al. Trends Mol Med. 2011 Jan;17(1):47-55. doi: 10.1016/j.molmed.2010.09.006. Trends Mol Med. 2011. PMID: 20971039 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials